Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Notice of Proposed Sale · 144

Dare Bioscience, Inc.

DARENASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Nov 19, 2026Accepted Nov 19, 2026, 4:09 PM ESTFiling CIK 1401914Accession 0001950047-26-011339
Share

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer
DARE BIOSCIENCE, INC.
Issuer CIK
0001401914
SEC file number
001-36395
Phone
(858) 926-7655
Person for whose account securities are to be sold
RASTETTER FAMILY TRUST
Relationships to issuer
Director
Street
3655 Nobel Drive
Street (continued)
Suite 260
City
San Diego
State / country code
CA
Postal code
92122

Securities proposed for sale

Securities proposed for sale · 1 reported row
SecurityProposed unitsAggregate market valueUnits outstandingApproximate sale dateExchangeBroker / market maker
Common859382.2619,669,00011/19/2026NASDAQMorgan Stanley Smith Barney LLC Executive Financial Services

Broker / market maker — proposed row 1, entry 1

Name
Morgan Stanley Smith Barney LLC Executive Financial Services
Street
1 New York Plaza
Street (continued)
8th Floor
City
New York
State / country code
NY
Postal code
10004

Acquisition of securities to be sold

Acquisition of securities to be sold · 14 reported rows
SecurityAcquiredNature of acquisitionAcquired fromAmount acquiredGift transactionPayment dateNature of payment
Common10/01/2016Board Comp.Issuer148N10/01/2016Compensation
Common05/08/2007Various Private Investments in Cerulean - Pre-IPOIssuer59N05/08/2007Cash
Common04/15/2014Various Private Investments in Cerulean - Pre-IPOIssuer41N04/15/2014Cash
Common04/15/2014Various Private Investments in Cerulean - Pre-IPOIssuer42N04/15/2014Cash
Common06/15/2011Various Private Investments in Cerulean - Pre-IPOIssuer21N06/15/2011Cash
Common01/03/2017Board Comp.Issuer6N01/03/2017Compensation
Common12/07/2007Various Private Investments in Cerulean - Pre-IPOIssuer21N12/07/2007Cash
Common11/30/2012Various Private Investments in Cerulean - Pre-IPOIssuer28N11/30/2012Cash
Common01/03/2017Board Comp.Issuer203N01/03/2017Compensation
Common12/02/2011Various Private Investments in Cerulean - Pre-IPOIssuer35N12/02/2011Cash
Common04/17/2014IPOIssuer157N04/17/2014Cash
Common10/03/2016Board Comp.Issuer4N10/03/2016Compensation
Common07/13/2009Various Private Investments in Cerulean - Pre-IPOIssuer48N07/13/2009Cash
Common11/12/2010Various Private Investments in Cerulean - Pre-IPOIssuer46N11/12/2010Cash

Prior-sale reporting

Nothing to report for the preceding three months
Y

Notice signature

Notice date
11/19/2026
Signed
/s/ William H Rastetter, Trustee

Company context

We are a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation we advance is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, we’re working to close critical gaps in care using science that serves her needs. In March 2025, we announced an expansion of our business model to include a dual-path approach to bringing new products to market. For select proprietary formulations, we are pursuing both traditional FDA approval and earlier market access via Section 503B compounding. We believe this strategy allows us to respond to clinician and patient demand for timely access while continuing to generate the data necessary to seek FDA approval and support long-term value creation. In addition to prescription-based offerings — both FDA-approved products and compounded drugs — we intend to bring to market select consumer health products that do not require a physician’s prescription, where appropriate based on product profile and market opportunity.

Current securities

Recent company filings

  1. 4 filingNov 20, 2026
  2. Results of Operations and Financial ConditionNov 16, 2026
  3. 10-Q filingNov 16, 2026
  4. Submission of Matters to a Vote of Security HoldersNov 12, 2026
  5. DEFA14A filingOct 27, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.